Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Press Release

— Herbert Y. Meltzer, MD; Karl Deisseroth, MD, PhD; Robert C. Malenka, MD, PhD; Michael P. Bogenschutz, MD; and Peter Hendricks, PhD, bring decades of clinical and research expertise in psychiatry, addiction, behavioral health, and pharmacology to guide Company’s development programs — –Scientific Advisory Board members are affiliated with cutting-edge programs at elite academic and…

Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

Press Release

— Review of Phase I ready BMB-101 and upcoming milestones — — Conference call to be held on May 19, 2022, 10:00am ET —   Vancouver, BC – April 19, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the…

Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial

Press Release

Vancouver, BC – March 14, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announcedthe successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101. Importantly, there were…

Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference

Press Release

Vancouver, BC – March 8, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Company managementwill present virtually at the Oppenheimer 32nd Annual Healthcare Conference as follows:  …

Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

Press Release

Vancouver, BC – January 4, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and Alan Kozikowski, PhD, Chief Scientific Officer, will present…